Novel carbazole and acyl-indole antimitotics

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 11, 2009, Pages 3078-3080

  Barta, Thomas E ^a   Barabasz, Amy F ^b   Foley, Briana E ^c   Geng, Lifeng ^d   Hall, Steven E ^e   Hanson, Gunnar J ^f   Jenks, Matthew ^g   Ma, Wei ^e   Rice, John W ^e   Veal, James ^h  

^a Carrboro   (United States)

^b KBI Biopharma Inc   (United States)

^c Zen Bio Inc   (United States)

^d Philip Morris   (United States)

^e Joyant Pharmaceuticals ^*

^f Joyant Pharmaceuticals   (United States)

^g Scynexis Inc   (United States)

^h Pamlico Pharmaceutical Inc   (United States)

Author keywords

Antimitotic; Antiproliferative; Cancer; Carbazole; Colchicine; Oncology; Tubulin

Indexed keywords

ANTIMITOTIC AGENT; BENZAMIDE; CARBAZOLE DERIVATIVE; COLCHICINE; COMBRETASTATIN; DEMECOLCINE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NOCODAZOLE; TUBULIN; VINBLASTINE;

ARTICLE; DRUG ACTIVITY; HUMAN; HUMAN CELL; IC 50; MICROTUBULE ASSEMBLY; STRUCTURE ACTIVITY RELATION;

EID: 65149096798     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.010     Document Type: Article

References (14)

1. Bacher G., Beckers T., Klenner T., Kuscher B., and Nickel B. Pure Appl. Chem. 73 (2001) 1459
2. Cragg G.M., and Newman D.J. J. Nat. Prod. 67 (2004) 232
3. Kuppens I.E.L.M. Curr. Clin. Pharm. 1 (2006) 57
4. Nguyen T.L., McGrath C., Hermone A.R., Burnett J.C., Zaharevitz D.W., Day B.W., Wipf P., Hamel E., and Gussio R. J. Med. Chem. 48 (2005) 6107
5. Pelletier P.S., and Caventon J. Ann. Chim. Phys. 14 (1820) 69
6. Pettit G.R., Singh S.B., Boyd M.R., Hamel E., Pettit R.K., Schmidt J.M., and Hogan F. J. Med. Chem. 38 (1995) 1666-1672
7. Koyanagi N., Nagasu T., Fujita F., Watanabe T., Tsukahara K., Funahashi Y., Fujita M., Taguchi T., Yoshino H., and Kitoh K. Cancer Res. 54 (1994) 1702
8. De Brabander M.J., Van de Veire R.M.L., Aerts F.E.M., Borgers M., and Janssen P.A.J. Cancer Res. 36 (1976) 905
9. For examples of carbazoles with HSP90 activity, see:. Veal J.M., Barta T.E., Rice J.W., Partridge J.M., Fadden P., Ma W., Jenks M., Geng L., Hanson G.J., Huang K.H., Barabasz A.F., Foley B.E., Otto J., and Hall S.E. Bioorg. Med. Chem. Lett. 18 (2008) 3517
10. 3 For a description of the technology, see:. Graves P.R., Kwick J.J., Fadden P., Ray R., Hardeman K., Coley A.M., Foley M., and Haystead T.A. J. Mol. Pharmacol. 62 (2002) 1364
11. Barabasz A., Foley B., Otto J.C., Scott A., and Rice J. Assay Drug Dev. Technol. 4 (2006) 153 Compound 6a is identified as SC-103232 in this Letter
12. Juan G., Traganos F., James W.M., Ray J.M., Roberge M., Sauve D.M., Anderson H., and Darzynkiewicz Z. Cytometry 32 (1998) 71
13. Hanson, G. J.; Barta, T. E.; Geng, L.; Huang, K. H.; Veal, J. PCT Int. Appl. WO 2007035620; Chem. Abstr. 2007, 146, 379821.
14. Kawada A., Mitamura S., and Kobayashi S. J. Chem. Soc., Chem. Commun. (1993) 1157